Australië - Engels - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - flumazenil, quantity: 0.1 mg/ml - injection, solution - excipient ingredients: water for injections; acetic acid; sodium chloride; sodium hydroxide; disodium edetate - flumazenil kabi is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil. not to be used in outpatients or short stay patients. not to be used as a diagnostic.

Verenigde Staten - Engels - NLM (National Library of Medicine)

a-s medication solutions - flumazenil (unii: 40p7xk9392) (flumazenil - unii:40p7xk9392) - flumazenil 0.1 mg in 1 ml - flumazenil injection, usp is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. flumazenil injection, usp is indicated for the reversal of conscious sedation induced with benzodiazepines (see precautions: pediatric use ). flumazenil is contraindicated: - in patients with a known hypersensitivity to flumazenil or benzodiazepines. - in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). - in patients who are showing signs of serious cyclic antidepressant overdose (see warnings ). flumazenil acts as a benzodiazepine antagonist, blocks the effect of benzodiazepines in animals and man, antagonizes benzodiazepine reinforcement in

Australië - Engels - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amphotericin b, quantity: 10 mg - lozenge - excipient ingredients: acacia; mannitol; polyvinyl alcohol; saccharin sodium; sodium cyclamate; purified talc; stearic acid; flavour - treatment of candidal infections of the oral and perioral areas including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by the overgrowth of candida albicans.

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

omega pharma ltd - nicotine - lozenge - 1.5mg

Ierland - Engels - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - flumazenil - solution for injection - 0.1 milligram(s)/millilitre - antidotes; flumazenil

Singapore - Engels - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - flumazenil - injection, solution - flumazenil 0.1mg/ml

Singapore - Engels - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - flumazenil - injection, solution - flumazenil 0.1 mg/ml

Singapore - Engels - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - flumazenil - injection, solution - flumazenil 0.1 mg/ml

Singapore - Engels - HSA (Health Sciences Authority)

zyfas pharma pte ltd - flumazenil - solution, sterile - flumazenil 0.1 mg per ml

Australië - Engels - Department of Health (Therapeutic Goods Administration)

johnson & johnson pacific pty ltd - benzocaine, quantity: 8 mg - lozenge - excipient ingredients: purified water; acesulfame potassium; magnesium stearate; macrogol 6000; xanthan gum; sucralose; titanium dioxide; hypromellose; mannitol; polysorbate 80; macrogol 400; flavour - anaesthetic lozenges for symptomatic relief of sore throats